SBL Session Vaccines for COVID A new challenge a new development

10 de December de 2020

On December 17, Antonio Fernández, M.D. Director, Business Development & Government Affairs of Johnson & Johnson, gives an online presentation under the title “Vaccines for COVID. A new challenge, a new development ”.

Antonio Fernández has a degree in Medicine from the University of Navarra and a graduate of the Executive Development Program of the Kellogg Management School, Northwestern University (Chicago, USA). In addition, he has received postgraduate training from the Karolinska Institutet (Sweden) and the London School of Economics and Political Science (UK), among others.

Throughout his 33-year professional career at Johnson & Johnson he has been Medical Director of Janssen in Spain and has also worked as Director of Clinical Research for the Janssen Research Foundation in Beerse, Belgium. He was subsequently appointed Executive Director and Global Leader of the Neurosciences area at Johnson & Johnson based in New Jersey, USA. He has also been responsible for the Neuroscience New Product Development (NBD) areas at Janssen EMEA (Europe, Middle East and Africa). He is currently Director of Janssen Spain and is responsible for the Market Access and Government Affairs Areas.

In 2017, during the Johnson & Johnson Global Market Access Conference in Boston, USA Antonio was distinguished with a Lifetime Achievement Award for Exceptional Business Contribution. 

In 2019, Antonio announced his wish to retire early at the end of 2020, although he will continue to collaborate on specific projects with some teams from Janssen EMEA in the future.

In 2020, since the start of the development of the Janssen vaccine for COVID-19, Antonio has worked in coordination with the Global Clinical Operations teams in Spain and Global Regulatory Affairs in the USA to launch Phase Clinical Trials. 2 and 3 of the Janssen vaccine in Spain.

Contents of the presentation:

• Brief introduction to genetic vaccines for COVID-19

• Most relevant characteristics of the Janssen vaccine

• Presentation of preclinical and clinical data available in the public domain

• Some relevant aspects that must be taken into account when evaluating different immunization options against COVID-19

The session, 17 December at 8.15 am,  is organized by the Marqués de Valdecilla Research Institute within the Valdecilla General Sessions program that are held on Thursdays.